莫沙必利治疗功能性消化不良多中心双盲对照研究  

Mosapride in treating functional dyspepsia: a multicenter, double-blind study

作　　者：王振华[1] 达四平[2] 龚能平[3] 吴良才 赵聪[5] 蒋明德[6] 

机构地区：[1]中国人民解放军第三军医大学附属西南医院消化内科,重庆400038 [2]中国人民解放军第三军医大学附属新桥医院消化内科,重庆400037 [3]重庆医科大学第一附属医院消化内科,重庆400013 [4]重庆医科大学第二附属医院消化内科,重庆400010 [5]成都市第三人民医院消化内科,四川成都610031 [6]中国人民解放军成都军区总医院消化内科,四川成都610083

出　　处：《中国新药与临床杂志》2000年第5期363-366,共4页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：目的 :观察莫沙必利治疗功能性消化不良的有效性及安全性。方法 :采用双盲随机对照研究 ,2 55名功能性消化不良病人。随机分为 2组 :莫沙必利组 12 7例 (男性 58例 ,女性 6 9例 ,年龄 4 0a±s 12a)用莫沙必利 5mg ,po ,tid ;多潘立酮组 12 8例(男性 6 1例 ,女性 6 7例 ;年龄 39a± 12a)用多潘立酮 10mg ,po ,tid。疗程均为 4wk。结果 :莫沙必利治疗 4wk ,上腹疼痛、上腹饱胀、嗳气、进食减少及早饱等症状的总有效率分别为 77.8% ,86 .6 % ,82 .5% ,87.3% ,87.2 %。明显高于多潘立酮的6 3.5% ,75.0 % ,6 9.6 % ,74 .1% ,74 .5%。莫沙必利组治疗后胃半排空时间缩短 15min± 13min ,明显高于多潘立酮组 5min± 16min。结论 :莫沙必利是一种新型安全有效的治疗功能性消化不良的药物。AIM: To evaluate the clinical efficacy and safety of mosapride in treating functional dyspepsia. METHODS: Two hundred and fifty five patients with functional dyspepsia were divided into two groups. Group mosapride of 127 patients (M 58, F 69; age 40 a± s 12 a) was treated with mosapride 5 mg po , tid for 4 wk. Group domperidone of 128 patients (M 61, F 67; age 39 a±12 a) was treated with domperidone 10 mg, po ,tid for 4 wk. RESULTS: In the group mosapride, the total effective rates of mosapride in treating epigastric pain, epigastric fullness, belch, decrease of food intake, early satiety were respectively 77.8%, 86.6%, 82.5%, 87.3% and 87.2%, they were higher than 63.5%, 75.0%, 69.6%, 74.1% and 74.5% in the group domperidone. The gastric half emptying time shortened for 15 min±13 min after treatment in the group mosapride. It was much longer than 5 min±16 min in the group domperidone. CONCLUSION: Mosapride is a new safe efficacious drug in treating functional dyspepsia.

关 键 词：莫沙必利 功能性消化不良 药物疗法 

分 类 号：R570.5[医药卫生—消化系统] R975.1[医药卫生—内科学]